Severe Sjögren's syndrome
62-year-old woman with autoimmune dry eye, intolerant to cyclosporine and unresponsive to plugs, lubricants, and lifitegrast.
Why Q‑ASED fits: Autologous serum delivers the growth factors and anti-inflammatory cytokines her own tear film is missing.
50% concentration · 6× daily · quarterly subscription
Persistent post-LASIK dry eye
34-year-old patient 6 months post-LASIK with chronic burning, fluctuating vision, and corneal sensitivity loss despite aggressive lubrication.
Why Q‑ASED fits: Q‑ASED supports neural and epithelial recovery — faster sensitivity return and durable symptom relief.
20% concentration · 4× daily · monthly subscription
Ocular GVHD post-transplant
48-year-old bone marrow transplant survivor with progressive ocular surface breakdown and reduced quality of life.
Why Q‑ASED fits: Serum components directly address the inflammatory environment that artificial tears can't reach.
50% concentration · 8× daily · monthly subscription
Neurotrophic keratitis
Diabetic patient with stage 1–2 neurotrophic keratopathy and recurrent epithelial defects.
Why Q‑ASED fits: Growth factors in autologous serum promote epithelial healing where bandage lenses have plateaued.
20% concentration · 6× daily · monthly subscription
Refractory severe dry eye
Long-standing dry eye on the full pharmaceutical ladder — restasis, xiidra, plugs, warm compresses — with persistent symptoms.
Why Q‑ASED fits: When standard therapy plateaus, biological replacement is the logical next step before more invasive options.
20% concentration · 4–6× daily · quarterly subscription
Chemical or thermal burn recovery
Patient recovering from a chemical injury with persistent epithelial defect and limbal stem cell stress.
Why Q‑ASED fits: Autologous serum supports limbal recovery and re-epithelialization during the critical healing window.
50% concentration · hourly initially, tapered · monthly subscription
